Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin

Clinical Pharmacokinetics

Volumn 52, Issue 9, 2013, Pages 805-813

  Brennan, Barbara J ^a   Moreira, Sebastian A ^a   Morcos, Peter N ^a   Navarro, Mercidita T ^b   Asthappan, Jiney ^a   Goelzer, Petra ^a   Weigl, Paul ^a   Smith, Patrick F ^c,d  

^a HOFFMANN LA ROCHE INC   (United States)

^b GENENTECH INC   (United States)

^c D3 Medicine   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DANOPREVIR; RITONAVIR;

ABDOMINAL DISCOMFORT; ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; GASTROENTERITIS; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE; MALE; NAUSEA; NONHUMAN; NORMAL HUMAN; OPEN STUDY; PH; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE; VITAL SIGN;

ADULT; ANIMALS; ANTIVIRAL AGENTS; CHO CELLS; CRICETULUS; CROSS-OVER STUDIES; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; HUMANS; LACTAMS; MALE; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; RITONAVIR; SULFONAMIDES;

EID: 84883178669     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0077-2     Document Type: Article

References (33)

1. Everson GT, Cooper C, Hézode C, et al. High SVR rates with 12 to 24 weeks of ritonavir-boosted danoprevir plus Peg-IFNα-2a (40KD)/RBV in HCV genotype 1 or 4 patients in the DAUPHINE study. Hepatology. 2012;56(4 Suppl):552A.
2. Gane EJ, Rouzier R, Stedman C, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. J Hepatol. 2011;55(5):972-9.
3. Reddy MB, Chen Y, Haznedar JO, et al. Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study. Clin Pharmacokinet. 2012;51(7):457-65.
4. Goelzer P, Morcos PN, Tran J, et al. Coadministration of ritonavir with the HCV protease inhibitor danoprevir substantially reduces reactive metabolite formation both in vitro and in vivo. Hepatology. 2012;56(4 Suppl):580A.
5. Eley T, Han Y-H, Huang S-P, et al. In vivo and in vitro assessment of asunaprevir as an inhibitor and substrate of OATP transporters in healthy volunteers. Rev Antivir Ther Infect Dis. 2012;6:7.
6. Park S, Ward W, Beaudet B, et al. In vitro assessment of potential drug-drug interactions between telaprevir and cyclophilin inhibitors in the treatment of chronic hepatitis C. Hepatology. 2011;54(Suppl S1):540A.
7. Reddy MB, Morcos PN, Le Pogam S, et al. Pharmacokinetic/pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors. Antimicrob Agents Chemother. 2012;56(6):3144-56.
8. Seiwert SD, Andrews SW, Jiang Y, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother. 2008;52(12):4432-41.
9. Portmann R, Meille C, Poirier A. Danoprevir: in vitro studies on hepatic active uptake in human hepatocytes. Nutley: Hoffmann-La Roche Inc; 2012 (data on file).
10. Wen B, Huang J. In vivo metabolism of danoprevir. Nutley: Hoffmann-La Roche Inc; 2012 (data on file).
11. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215-36.
12. Shitara Y, Maeda K, Ikejiri K, et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 2013;34(1):45-78.
13. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077-80. (Pubitemid 23099291)
14. Treiber A, Schneiter R, Häusler S, et al. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007;35(8):1400-7. (Pubitemid 47121782)
15. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004;76(2):167-77. (Pubitemid 39013406)
16. Park JW, Siekmeier R, Merz M, et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther. 2002;40(10):439-50.
17. Binet I, Wallnöfer A, Weber C, et al. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. 2000;57:224-31. (Pubitemid 30227769)
18. Neoral® (cyclosporine capsules, USP). US prescribing information. New Jersey: Novartis Pharmaceuticals Corporation; 2012.
19. Morcos PN, Moreira S, Navarro M, et al. Ritonavir-boosted danoprevir (DNVr) may be co-administered without regard to meals or in combination with ranitidine or omeprazole: results of a healthy volunteer pharmacokinetic study. Rev Antiviral Ther Infect Dis. 2012;6:7.
20. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693-705.
21. Ding R, Tayrouz Y, Reidel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther. 2004;76(1):73-84. (Pubitemid 38844736)
22. Vaidyanathan S, Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008;48(11):1323-38.
23. Keogh J, Kunta J. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci. 2006;27(5):543-54. (Pubitemid 43372051)
24. Reddy MB, Connor A, Brennan BJ, et al. Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible. Biopharm Drug Dispos. 2011;32(5):261-75.
25. Asberg A, Hartmann A, Fjeldsa E, et al. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant. 2001;1(4):382-6. (Pubitemid 33681704)
26. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 1997;62(3):311-21. (Pubitemid 27417797)
27. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 1993;25(4):2732-4. (Pubitemid 23239614)
28. Drewe J, Gutmann H, Fricker G, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999;57:1147-52. (Pubitemid 29171690)
29. Morcos PN, Chang L, Zhang Y, et al. Danoprevir (DNV) does not change effects of ritonavir (RTV) on the PK of CYP3A substrate midazolam (MDZ) and CYP2C9 substrate warfarin (WAR). Rev Antiviral Ther Infect Dis. 2011;6:4.
30. Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther. 1995;58(1):15-9.
31. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35(4):275-91. (Pubitemid 28491214)
32. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transplant. 2004;10(7):939-44. (Pubitemid 38979268)
33. Guaraldi G, Cocchi S, Codeluppi M, et al. Pharmacokinetic interaction between amprenavir/ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplant Proc. 2006;38(4):1138-40. (Pubitemid 43815874)